Company Filing History:
Years Active: 2001-2008
Title: Innovations in Cancer Treatment by Inventor John C. Hiserodt
Introduction
John C. Hiserodt is an accomplished inventor based in Huntington Beach, CA, with a remarkable portfolio of six patents. His pioneering work focuses on novel pharmaceutical compositions and methods aimed at enhancing cancer treatment, specifically through innovative immunotherapy strategies. Hiserodt's inventions represent significant advancements in the quest to develop effective cancer vaccines and therapies.
Latest Patents
One of Hiserodt's latest patents involves a pharmaceutical composition for cancer treatment that utilizes cells expressing a membrane cytokine. This invention introduces cellular vaccines aimed at immunotherapy, particularly in humans. The vaccines include a source of tumor-associated antigens and a cytokine-secreting cell line, which may consist of primary tumor cells, tumor cell lines, or tumor extracts prepared from the subject. In certain embodiments, the cytokine-secreting line is genetically altered to produce an elevated level of cytokines such as IL-4, GM-CSF, IL-2, TNF-α, and M-CSF. These cytokine-producing cells are designed to immunostimulate the host's immune response against the tumor antigen.
Another significant patent focuses on methods and compositions for treating tumors using implants comprising combinations of allogeneic cells. This innovative approach utilizes alloactivated lymphocytes from either the patient or third-party donors. The cells are alloactivated in a mixed lymphocyte culture and can be administered to the tumor bed or combined with tumor-associated antigens for vaccination purposes. This method not only enhances the effectiveness of the therapy but also provides ongoing immune protection against the tumor.
Career Highlights
John C. Hiserodt's career encompasses notable contributions to the field of cancer research and treatment. He has been associated with prominent institutions, including the University of California and Meyer Pharmaceuticals LLC, where he has played a pivotal role in advancing cancer-related therapies. His innovative spirit and dedication to research have positioned him as a leading figure in the development of novel immunotherapies.
Collaborations
Throughout his career, Hiserodt has collaborated with esteemed colleagues such as Gale Arthur Granger and Martin R. Graf. These partnerships have allowed for the sharing of knowledge and expertise, further enhancing the scope and impact of his innovations in cancer treatment.
Conclusion
John C. Hiserodt continues to be a significant contributor to the field of cancer immunotherapy through his innovative patents and collaborative efforts. His work not only reflects a deep understanding of the complexities of cancer treatment but also showcases the potential of cell-based therapeutics in the ongoing battle against cancer. As the medical community continues to explore the possibilities of Hiserodt's inventions, the hope for more effective cancer treatments becomes increasingly attainable.